Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

June 15, 2018: By Joan McKenna

Carmen Puliafito, MD

Ophthalmologist Carmen Puliafito, MD, took full blame for his use of meth and other drugs while dean at USC’s Keck School of Medicine, as the 67-year-old pleaded June 7 to keep his California medical license, according to The Los Angeles Times.

Puliafito told the administrative judge: “I was supposed to be a beacon of morality and judgment, and I fell flat on my face after decades of doing the right thing,” The Times reported.

The renowned retina specialist was testifying at a hearing that spanned two weeks and concluded June 8. The judge is expected to issue a ruling by early July.

Puliafito also apologized to those at the university for any harm he brought to them and to a woman named Sarah Warren for enabling her addiction, The Times reported.

Puliafito’s lawyer blamed his client’s poor judgment on bipolar disorder and a hypomanic state and said Puliafito had been in recovery for nearly a year.

The hearing was held almost a year after USC suspended Puliafito following allegations of drug use and partying with drug users, sometimes on campus, while dean from August 2007 to March 2016. He was still part of the Keck faculty and treating patients at the time of his suspension.

Puliafito had raised hundreds of millions of dollars as dean and recruited at least 70 professors. He also was a frequent speaker at ophthalmic meetings.

Puliafito resigned as dean in 2016 following an incident in which Warren, then 21, overdosed in his presence in a Pasadena hotel room and was rushed to a hospital before being released. Police made no arrests, even after finding meth in the hotel room. The Times began a 15-month investigation of Puliafito after receiving a tip about the episode. It published its findings July 17, 2017.

Puliafito’s medical license was suspended Sept. 22, 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023